CORT
Corcept Therapeutics Incorporated · Healthcare · Medical - Pharmaceuticals
Momentum-inputs (vergelijkbare managers):
breedte van houders -10.0% ·
aandelenstroom +1.9% ·
netto nieuwe posities -16.7%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +10 | 52.52M | $4.57B | +17 | −8 |
| Q1 2026 | 107 | -4 | 51.80M | $2.09B | +8 | −13 |
| Q4 2025 | 112 | 0 | 56.18M | $1.96B | +1 | n/a |
| Q3 2025 | 18 | -2 | 41.55M | $3.45B | +1 | −4 |
| Q2 2025 | 18 | +1 | 38.50M | $2.83B | +1 | n/a |
| Q1 2025 | 14 | +1 | 15.71M | $1.80B | +1 | n/a |
| Q4 2024 | 13 | 0 | 16.40M | $826.20M | n/a | n/a |
| Q3 2024 | 12 | -1 | 13.66M | $632.44M | n/a | −1 |
| Q2 2024 | 13 | n/a | 13.78M | $447.82M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 12.05M | -3.9% | $1.00B | 0.0% | ▼ Trim | 2 | SEC ↗ ×19 |
| 2 | The Vanguard Group ✦ (passief) | 9.54M | -1.5% | $792.63M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 6.09M | -2.8% | $506.09M | 0.7% | ▼ Trim | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passief) | 2.97M | +0.1% | $246.87M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 2.20M | +62.3% | $183.00M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 6 | Geode Capital Management ✦ (passief) | 1.93M | +1.0% | $161.53M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | JPMorgan Chase ✦ | 1.70M | n/a | $141.26M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 8 | AQR Capital Management ✦ | 1.51M | +546.9% | $125.26M | 0.1% | ▲ Add | 6 | SEC ↗ ×5 |
| 9 | Morgan Stanley ✦ | 1.19M | n/a | $98.65M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 10 | D. E. Shaw & Co. ✦ | 584.10K | -13.2% | $48.54M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 11 | Goldman Sachs Group ✦ | 389.09K | n/a | $32.34M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | T. Rowe Price ✦ | 383.06K | +160.4% | $31.84M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | Arrowstreet Capital ✦ | 369.39K | -53.2% | $30.70M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 305.95K | Nieuw | $25.43M | 0.1% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 175.63K | -32.6% | $14.60M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 111.59K | -75.0% | $9.27M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | Two Sigma Investments ✦ | 42.13K | -30.8% | $3.50M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 17.36K | +0.3% | $1.44M | 0.0% | ▲ Add | 6 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $25.43M | 0.1% |
Verlaten
| Norges Bank | $72.05M | was 0.0% |
| Adage Capital Partners | $7.06M | was 0.0% |
| Marshall Wace | $3.39M | was 0.0% |
| Wellington Management | $2.46M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 347 houders, 79.01M aandelen, $2.83B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 6.65K aand · $761,717
Director · 3.05K aand · $351,476
Director · 300 aand · $34,889
Officer · 15.84K aand · $1.84M
Officer · 4.74K aand · $552,869
Officer · 8.74K aand · $1.02M
Officer · 4.45K aand · $514,389
Officer · 5.15K aand · $600,063
Officer · 1.10K aand · $125,973
Officer · 2.09K aand · $241,412
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie